The Quantellect read.As of Nov 19, 2026, 7 active firms cover Foghorn Therapeutics Inc: 4 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $2.00 to $12.00 (about 6.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $7.83 sits 338% above the current $1.79. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-1.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy457%
Neutral343%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$7.83
+337.6% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.79 current
Highest Target$12.00
Average Target$7.83
Lowest Target$2.00
Detailed analyst forecasts for FHTX
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 4 of 7 active firms rate FHTX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
FHTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.26 – $-0.18 · 3 analysts · -21% YoY
Next period, 3 analysts expect Foghorn Therapeutics Inc to earn $-0.23 a share (range $-0.26 – $-0.18), versus $-0.29 a year earlier. Full-year consensus is $0.18, growing to $-1.11 the year after.
REVENUE · NEXT QUARTER
$12.5M
Range $12.5M – $12.5M · 3 analysts · +283% YoY
Revenue is expected to reach $12.5M (range $12.5M – $12.5M), +282.6% year-over-year. Full-year consensus is $103.7M, rising to $0 next year.
Top analysts covering Foghorn Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on FHTX.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$5.00+179.3% to target
Overall win rate
53%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #69
Neutral
No targeton FHTX
Overall win rate
51%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$13.00+626.3% to target
Overall win rate
45%
+ Follow
#4
Andres Y. Maldonado
HC Wainwright & Co. · Rank #288
Buy
$5.00+179.3% to target
Overall win rate
39%
+ Follow
#5
Robert Driscoll
Wedbush · Rank #490
Neutral
$2.00+11.7% to target
Overall win rate
32%
+ Follow
FHTX stock forecast FAQ
What is FHTX's average 12-month price target?+
The 6 active firms with a live target average $7.83 for Foghorn Therapeutics Inc over the next 12 months, ranging from a $12.00 high to a $2.00 low, as of Nov 19, 2026.
Is FHTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 4 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for FHTX?+
The Street-high target is $12.00 (Jefferies), and the Street-low is $2.00 (Wedbush). The average of all 6 active-firm targets is $7.83.
How many active Wall Street firms cover FHTX?+
7 active firms have a recognized rating on Foghorn Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering FHTX?+
Among analysts who currently cover FHTX, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $5.00 target.
What is Foghorn Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.26 – $-0.18) across 3 analysts. Full-year EPS is projected at $0.18, rising to $-1.11 the following year.
How much revenue is Foghorn Therapeutics Inc expected to report next quarter?+
Consensus revenue is $12.5M (range $12.5M – $12.5M). Full-year revenue is projected at $103.7M, growing to $0 next year.
Have analysts been upgrading or downgrading FHTX lately?+
As of Nov 19, 2026, 4 of 7 active firms rate FHTX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their FHTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.